Amicus Therapeutics (FOLD) Holder Sectoral Asset Management INC Has Cut Its Holding

February 15, 2018 - By Maria Brooks

Investors sentiment increased to 2.33 in Q3 2017. Its up 1.10, from 1.23 in 2017Q2. It increased, as 16 investors sold FOLD shares while 32 reduced holdings. 52 funds opened positions while 60 raised stakes. 192.70 million shares or 14.18% more from 168.77 million shares in 2017Q2 were reported. Amer Century Incorporated has 0% invested in Amicus Therapeutics, Inc. (NASDAQ:FOLD) for 86,328 shares. Moreover, Northern has 0.01% invested in Amicus Therapeutics, Inc. (NASDAQ:FOLD) for 1.98 million shares. 13.37M were accumulated by Blackrock. Nicholas Invest Prtn LP has 0.14% invested in Amicus Therapeutics, Inc. (NASDAQ:FOLD) for 134,388 shares. Moore Cap Mgmt Lp holds 0.03% or 100,000 shares in its portfolio. Moreover, Commonwealth Equity Ser has 0% invested in Amicus Therapeutics, Inc. (NASDAQ:FOLD) for 30,561 shares. Columbus Circle owns 199,874 shares for 0.05% of their portfolio. Dekabank Deutsche Girozentrale holds 0.01% or 70,900 shares in its portfolio. Price T Rowe Assoc Md holds 0.02% in Amicus Therapeutics, Inc. (NASDAQ:FOLD) or 8.09M shares. The Ohio-based Victory Capital Management has invested 0.08% in Amicus Therapeutics, Inc. (NASDAQ:FOLD). Wellington Grp Llp owns 6.06M shares. Aperio Limited Com owns 15,326 shares or 0% of their US portfolio. Ghost Tree Capital Ltd Liability holds 0.64% in Amicus Therapeutics, Inc. (NASDAQ:FOLD) or 200,000 shares. Secor Cap Advsr LP has invested 0.13% in Amicus Therapeutics, Inc. (NASDAQ:FOLD). 64,152 are held by Ubs Asset Management Americas.

Since October 12, 2017, it had 0 buys, and 16 selling transactions for $11.04 million activity. 32,500 shares valued at $517,371 were sold by Campbell Bradley L on Monday, January 22. HAYDEN DONALD J JR sold $300,002 worth of stock. The insider Barth Jay sold $71,268. The insider Andrews Kurt J. sold 10,000 shares worth $147,191. The insider Quimi Daphne sold 8,000 shares worth $117,723. Do Hung sold $715,360 worth of Amicus Therapeutics, Inc. (NASDAQ:FOLD) on Thursday, October 12.

Jerome Pfund decreased its stake in Amicus Therapeutics (FOLD) by 30.74% based on its latest 2017Q3 regulatory filing with the SEC. Sectoral Asset Management Inc sold 1.07M shares as the company’s stock rose 23.92% with the market. The hedge fund run by Jerome Pfund held 2.41 million shares of the health care company at the end of 2017Q3, valued at $36.39M, down from 3.48M at the end of the previous reported quarter. Sectoral Asset Management Inc who had been investing in Amicus Therapeutics for a number of months, seems to be less bullish one the $2.69 billion market cap company. The stock increased 3.22% or $0.505 during the last trading session, reaching $16.185. About 2.97M shares traded or 16.44% up from the average. Amicus Therapeutics, Inc. (NASDAQ:FOLD) has risen 12.45% since February 15, 2017 and is uptrending. It has underperformed by 4.25% the S&P500.

Sectoral Asset Management Inc, which manages about $3.30B and $776.31 million US Long portfolio, upped its stake in Cigna Corp (NYSE:CI) by 30,105 shares to 45,615 shares, valued at $8.53 million in 2017Q3, according to the filing.

Analysts await Amicus Therapeutics, Inc. (NASDAQ:FOLD) to report earnings on March, 7. They expect $-0.30 earnings per share, up 6.25 % or $0.02 from last year’s $-0.32 per share. After $-0.41 actual earnings per share reported by Amicus Therapeutics, Inc. for the previous quarter, Wall Street now forecasts -26.83 % EPS growth.

More notable recent Amicus Therapeutics, Inc. (NASDAQ:FOLD) news were published by: Globenewswire.com which released: “Amicus Therapeutics Announces Presentations and Posters at 14th Annual …” on January 22, 2018, also Seekingalpha.com with their article: “Amicus Therapeutics: What To Expect In 2018” published on January 24, 2018, Seekingalpha.com published: “Amicus Therapeutics: Pompe Data Strengthens Bullish Thesis” on February 08, 2018. More interesting news about Amicus Therapeutics, Inc. (NASDAQ:FOLD) were released by: Globenewswire.com and their article: “Amicus Therapeutics Launches Galafoldâ„¢ (Migalastat) for Treatment of Fabry …” published on January 17, 2018 as well as Seekingalpha.com‘s news article titled: “Amicus Therapeutics: Positive Data For Pompe Disease And Recent Regulatory …” with publication date: February 13, 2018.

Amicus Therapeutics, Inc. (NASDAQ:FOLD) Ratings Coverage

Among 9 analysts covering Amicus Therapeutics (NASDAQ:FOLD), 8 have Buy rating, 0 Sell and 1 Hold. Therefore 89% are positive. Amicus Therapeutics had 22 analyst reports since August 18, 2015 according to SRatingsIntel. The rating was initiated by Robert W. Baird with “Neutral” on Thursday, April 14. The rating was maintained by Cowen & Co on Sunday, June 25 with “Buy”. The rating was initiated by Goldman Sachs with “Neutral” on Wednesday, March 30. Leerink Swann maintained Amicus Therapeutics, Inc. (NASDAQ:FOLD) rating on Thursday, February 8. Leerink Swann has “Outperform” rating and $24 target. As per Monday, August 7, the company rating was maintained by Cowen & Co. The firm earned “Buy” rating on Monday, August 31 by Leerink Swann. The stock has “Buy” rating by Chardan Capital Markets on Monday, October 5. The firm has “Buy” rating by Cowen & Co given on Tuesday, September 1. The company was upgraded on Tuesday, March 8 by Janney Capital. Leerink Swann maintained the stock with “Outperform” rating in Monday, October 5 report.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.